Access to anti-retroviral drugs, female in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
Middle East, North Africa, Afghanistan & Pakistan (excluding high income): Access to anti-retroviral drugs, female was 38.4% in 2024. ◆ Volatile
Access to anti-retroviral drugs, female in Middle East, North Africa, Afghanistan & Pakistan (excluding high income), 2000–2024
Source: UNAIDS estimates. Measured in %.
Analysis
Middle East, North Africa, Afghanistan & Pakistan (excluding high income) recorded 38.4% for access to anti-retroviral drugs, female in 2024. That is the highest value across all 25 years on record.
Compared with earlier readings it is up 5.4% on the previous year and up 98.3% over ten years.
Over the whole period, access to anti-retroviral drugs, female in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) peaked at 38.4% in 2024 and was at its lowest, 0.4%, in 2000.
The series is highly variable year to year, so single readings are best treated with caution.
Access to anti-retroviral drugs, female in Middle East, North Africa, Afghanistan & Pakistan (excluding high income), year by year
| Year | % | Change |
|---|---|---|
| 2000 | 0.4% | — |
| 2001 | 0.6% | +45.6% |
| 2002 | 0.8% | +27.8% |
| 2003 | 2.9% | +272.2% |
| 2004 | 2.9% | +0.1% |
| 2005 | 3.8% | +31.2% |
| 2006 | 4.8% | +27.0% |
| 2007 | 5.8% | +21.6% |
| 2008 | 7.0% | +20.3% |
| 2009 | 8.9% | +27.0% |
| 2010 | 10.9% | +21.8% |
| 2011 | 12.2% | +11.9% |
| 2012 | 14.7% | +21.1% |
| 2013 | 16.7% | +13.3% |
| 2014 | 19.4% | +16.1% |
| 2015 | 21.1% | +8.8% |
| 2016 | 23.8% | +13.0% |
| 2017 | 26.0% | +9.1% |
| 2018 | 28.6% | +10.0% |
| 2019 | 30.0% | +4.9% |
| 2020 | 30.2% | +0.6% |
| 2021 | 32.9% | +9.1% |
| 2022 | 33.8% | +2.8% |
| 2023 | 36.4% | +7.7% |
| 2024 | 38.4% | +5.4% |
Biggest year-on-year movements
Years where Access to anti-retroviral drugs, female in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.
| Year | Change | From | To |
|---|---|---|---|
| 2003 | +272.2% | 0.8% | 2.9% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 3.8% | 0.4% | 8.9% | 10 |
| 2010s | 20.3% | 10.9% | 30.0% | 10 |
| 2020s | 34.3% | 30.2% | 38.4% | 5 |
Countries ranked near Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
- 19 Cameroon 95.0% compare
- 19 Sierra Leone 95.0% compare
- 19 Tajikistan 95.0% compare
More gender data for Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
- Labor force, female 43.88 million (2025)
- Labor force, female, per capita 0.0582 units per person (2025)
- Labor force, female, per unit of GDP 0 units per US$ of GDP (2025)
- Labor force, female, annual growth rate 2 % change on previous year (2025)
- Labor force, female, per square kilometre 4.23 units per square kilometre (2023)
- Ratio of female to male youth unemployment rate (% ages 15-24) 163.7% (2025)
- School life expectancy, primary to tertiary, female 12.68 years (2018)
- School life expectancy, primary to tertiary, male 13.14 years (2018)
- Proportion of women in ministerial level positions 13.2% (2025)
- Own-account workers, female (% of female employment) 15.9% (2016)
All data for Middle East, North Africa, Afghanistan & Pakistan (excluding high income) →
Frequently asked questions
- What is access to anti-retroviral drugs, female in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- Access to anti-retroviral drugs, female in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) was 38.4% in 2024, according to UNAIDS estimates.
- What is the highest access to anti-retroviral drugs, female recorded in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- The highest recorded value was 38.4% in 2024.
- What is the lowest access to anti-retroviral drugs, female recorded in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- The lowest recorded value was 0.4% in 2000.
- How does Middle East, North Africa, Afghanistan & Pakistan (excluding high income) rank for access to anti-retroviral drugs, female?
- Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 18th out of 19 groups with data for 2024.
- Is access to anti-retroviral drugs, female rising or falling in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- Over the last ten years it is up 98.3%. The long-run trend across the full record is volatile.
- Where does this Middle East, North Africa, Afghanistan & Pakistan (excluding high income) data come from?
- The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.